Extended-spectrum ?-Lactamases-producing Klebsiella pneumoniae and Escherichia coli: Clinical Distribution and Antibiotic Resistance
- VernacularTitle:大肠埃希菌与肺炎克雷伯菌超广谱?-内酰胺酶的临床分布及药敏性分析
- Author:
Qunying CHEN
;
Minghai HUANG
- Publication Type:Journal Article
- Keywords:
Escherichia coli;
Klebsiella pneumoniae;
ESBLs;
Drug resistanc
- From:
Chinese Journal of Nosocomiology
2006;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To study the clinical distribution and the drug resistance of extended-spectrum ?-lactamases (ESBLs) producing Klebsiella pneumoniae and Escherichia coli. METHODS The clinical isolates were identified by VITEK-60 of Bio-Merieux of France. K-B agar diffusion method and confirmed test were used to detect the drug resistance of ESBLs-producing K. pneumoniae and E. coli. RESULTS The incidence of ESBLs was 52.8% in E. coli and 63.5% in K. pneumoniae. E. coli was mostly isolated from urine (22.1%). The second was isolated from pus/wound (11.7%). Majority strains were isolated from surgical and pediatric wards. K. pneumoniae was mostly isolated from sputum and throat swab (37.8%), 21.8% from neonate ward and 16% from child ICU. CONCLUSIONS To cure infections caused by ESBLs-producing K. pneumoniae and E. coli, imipenem is the best choice and piperacillin/tazobactam is the second choice.
